Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination With Chemotherapy in Participants With High-Risk Neuroblastoma

NCT07549321 is registered in ClinicalTrials.gov with Renaissance Pharma Ltd. as lead sponsor.

NCT NCT07549321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07549321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination With Chemotherapy in Participants With High-Risk Neuroblastoma
Lead sponsor
Renaissance Pharma Ltd.
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 30, 2026
Completion date
March 31, 2031
Enrollment
144 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk neuroblastoma